Cost-Effectiveness of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy

This publication has 49 references indexed in Scilit:

• Chemotherapy-induced nausea and vomiting in routine practice: a European perspective
  Supportive Care in Cancer, 2004
• Nausea and Vomiting Remain a Significant Clinical Problem
  Journal of Pain and Symptom Management, 2000
• Consensus proposal for 5HT 3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy
  Supportive Care in Cancer, 1998
• An Introduction to Markov Modelling for Economic Evaluation
  PharmacoEconomics, 1998
• Alternatives to the QALY measure for economic evaluations
  Supportive Care in Cancer, 1997
• Economic foundations of cost-effectiveness analysis
  Journal of Health Economics, 1997
• Cost and Cost-Effectiveness Analysis of Ondansetron Versus Metoclopramide Regimens†
  PharmacoEconomics, 1994
• The real costs of emesis—An economic analysis of ondansetron vs. Metoclopramide in controlling emesis in patients receiving chemotherapy for cancer
  European Journal Of Cancer, 1993
• Comparison of the 5-Hydroxytryptamine₃(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis
  New England Journal of Medicine, 1990
• On the receiving end—patient perception of the side-effects of cancer chemotherapy
  European Journal of Cancer and Clinical Oncology, 1983